Is body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial

Affiliation auteurs!!!! Error affiliation !!!!
TitreIs body mass index (BMI) associated with favorable outcomes in metastatic renal cell carcinoma (mRCC) treated with nivolumab? An ancillary study of the NIVOREN-GETUG AFU-26 trial
Type de publicationJournal Article
Year of Publication2020
AuteursColomba E, Dalban C, Flechon A, Chevreau C, Gravis G, Thibault C, Laguerre B, Barthelemy P, Borchiellini D, Goupil MGross, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume38
Date PublishedFEB 20
Type of ArticleMeeting Abstract
ISSN0732-183X